Yesterday, Bristol-Myers Squibb (BMY) lowered its fiscal 2009 outlook as a result of the split-off of pediatric nutrition company Mead Johnson Nutrition Co (MJN). Bristol-Myers expects earnings per share from continuing operations in the range of $1.75 -$1.80, down from its earlier guidance of $2.00 - $2.05. Earlier, in Nov, Bristol-Myers decided to split off its 83.1% holding in Mead Johnson.  Mead Johnson completed a public offering in Feb 2009. Since then, its shares have risen considerably. Following the completion of the spin-off, Bristol-Myers expects the transaction to be net cash flow positive to its biopharmaceutical business and accretive to earnings beginning in 2010. Earlier this month, the share swap ratio between the two companies was amended to 0.6313 shares of Mead Johnson per 1 Bristol-Myers common share from the earlier 0.6027. The offer expired on December 17.  The split-off would enable Bristol-Myers to operate ...

Bristol-Myers Squibb Co. (BMY), which intends to split its 83.1% stake in the Nutritional segment to concentrate exclusively on its biopharmaceutical business, announced that it will offer 0.6313 shares of Mead Johnson Nutrition Co.’s (MJN) common stock for each Bristol-Myers share in the exchange offer. The Nutritional segment operates under its subsidiary Mead Johnson and develops infant formulas such as Enfamil. The offer, which will witness Bristol-Myers exchange up to 170 million shares of its Nutritional segment, is set to end on Dec 17, 2009.   The offer will see Bristol-Myers accepting a maximum of 269.29 million shares of its common stock for exchange. The swap offer will be subject to proration if it is over-subscribed. In the event of the offer being consummated but not fully subscribed, Bristol-Myers intends to distribute any shares of Nutritional segment’s common stock it continues to own as a pro rata ...

Bristol-Myers (BMY), which intends to split-off its 83.1% holding in the Nutritional segment to concentrate on its core biopharmaceutical business, amended and extended the exchange offer regarding the Mead Johnson Shares. The Nutritional segment operates under its subsidiary Mead Johnson and develops infant formulas like Enfamil.   The company has increased its offer price to exchange up to 170 million shares of its Nutritional segment. The company also extended the expiry date of the offer to Dec 17 from Dec 14.   The split-off would enable Bristol-Myers to function as a fully independent biopharma company focusing exclusively on its pharmaceuticals segment, which manufactures and sells branded pharmaceutical drugs such as Pravachol for cholesterol reduction, Plavix for hypertension and Erbitux for cancer.   Plavix, the antiplatelet blood thinner indicated to reduce the risk of heart attack in patients with atherosclerosis, is the top growth driver for Bristol. However, patent ...

Bristol-Myers Squibb Co. (BMY) intends to split its 83.1% holding in the Nutritional segment which operates under its subsidiary Mead Johnson and develops infant formulas such as Enfamil and other nutritional products. The move is aimed to enable the company to concentrate on its core biopharmaceutical business. The transaction is expected to be accretive to earnings beginning in 2010.  Under the terms of the deal, Bristol-Myers shareholders can exchange some, none or all of their shares of the company for shares of Mead Johnson common stock tax-free and at a discount. On completion, the exchange offer would enable Bristol-Myers to dispose of its entire holding interest in Mead Johnson.  For every $1 of Bristol-Myers stock exchanged, stockholders will get approximately $1.11 worth of Mead shares. The offer is set to expire on Dec 14, unless extended or terminated. Bristol-Myers owns 170 million shares of Mead Johnson. ...

It’s bold. It’s ambitious. And if it works, it should make America a healthier nation. Reform plans are a dime a dozen in Washington - many of which get stuck in political gridlock without ever reaching a satisfactory resolution. And healthcare reform is no different, with multiple presidents trying - and failing - to pass a plan that would see every American covered by healthcare insurance.

The Obama administration is the latest to step up to the plate and take a swing. And with Congress currently chewing over the details of its plan, it has healthcare investors shaking in the knees, wondering how an overhaul of the system will impact biotech, pharma, medical devices, insurers and other medical stocks.

Are their fears rational? And what are the best stocks to play? I’ve got three for you…

An American Healthcare Utopia

Imagine a world where poor Americans no longer have to ration their medication. A

...

Bristol-Myers Squibb Co. (BMY) recently declared a quarterly dividend of 31 cents per share, noting that it is payable on May 1 to stockholders of record at the close of business on April 3. BMY boasts an industry-leading yield of 6%.

< ?DART(15);?> Company Description

Bristol-Myers Squibb is a major producer and distributor of pharmaceuticals and other healthcare related products. The Pharmaceutical segment manufactures and sells branded pharmaceutical drugs such as Pravachol for cholesterol reduction, Plavix for hypertension and Erbitux for cancer.

Bristol Myers generates more than 55% of its revenue from the domestic market, and the balance from the international market primarily Europe, the Middle East and Asia.

Outstanding Income

The company recently declared a quarterly dividend of 31 cents per share, noting that it is payable on May 1 to stockholders of record at the close of business on April 3. BMY boasts an industry-leading yield of 6%.

Growth in

...

Bristol Myers Squibb Co. (BMY) boasts a solid record of exceeding analysts' earnings expectations, missing the consensus estimate only twice in more than 4 years. For the 2009 year, analysts see year-over-year earnings per share growth of 11%. The Street is forecasting earnings growth of 16% for the following year.

< ?DART(15);?> Company Description

Bristol-Myers Squibb is a major producer and distributor of pharmaceuticals and other healthcare related products. The Pharmaceutical segment manufactures and sells branded pharmaceutical drugs such as Pravachol for cholesterol reduction, Plavix for hypertension and Erbitux for cancer.

Bristol Myers generates more than 55% of its revenue from the domestic market, and the balance from the international market primarily Europe, the Middle East and Asia.

An IPO

Bristol-Myers feels confident enough, even amid current economic woes, to execute a partial offering of its Mead Johnson Nutrition (MJN) business.

BMY stated that it believes the initial public offering

...

Bristol-Myers Squibb Co. (BMY) has been outperforming the Dow Jones ($DJI), S&P 500 (SPX) and NASDAQ (COMP) after posting a strong third quarter. The company offers a rewarding dividend yield of 5.8%, while its industry peers pay no income. BMY's earnings per share are expected to grow by 25% over the next 3 – 5 year, which compares favorably to the industry average of 18%.

< ?DART(15);?> Company Description

Bristol-Myers Squibb is a major producer and distributor of pharmaceuticals and other healthcare related products. The Pharmaceutical segment manufactures and sells branded pharmaceutical drugs such as Pravachol for cholesterol reduction, Plavix for hypertension and Erbitux for cancer. The Nutritional segment, through its subsidiary Mead Johnson, develops infant formulas like Enfamil, as well as other nutritional products. Bristol Myers generates more than 55% of its revenue from the domestic market, and the balance from the international market primarily Europe, the

...

Indiana is perhaps best known by its world famous Indianapolis 500 motorsports race, but there is indeed much more to this state. It is also a fast growing and very diverse state. The following are interesting facts about Indiana:1. Livestock and poultry occupations employ over 42,000 in Indiana.2. There are three biodiesel plants in Indiana, and one under construction.3. There are 12 ethanol plants operating within the state and together they produce over 1 billion gallons of ethanol.4. A third of Indiana’s soybean production is exported.5. Indiana’s tourism industry contributes almost $7 billion to the economy.6. Indiana’s top manufacturing industries are: transportation equipment, chemicals, and primary metals.7. The manufacturing industry employs approximately 640,000 workers in the state.8. Indiana’s coal industry provides the state with over 2,000 jobs.9. International manufacturing firms with operations in Indiana employ ...